Forty patients enrolled across two dose levels — 8.6 mg/kg and 10 mg/kg every three weeks — is a modest number, but for CytomX it represents a completed optimization cohort and a direct on-ramp to a registrational trial discussion with FDA. That conversation is planned for later this year, with a first registrational study in late-line colorectal cancer targeted to start in the first half of 2027. The speed of that sequence depends entirely on what the 2H 2026 data readout actually shows, and that makes the upcoming monotherapy update the single most consequential data event in CytomX’s near-term history.
Varseta-M is an EpCAM-targeted PROBODY ADC carrying a topoisomerase-1 payload — and EpCAM is not a marginal target in colorectal cancer. It is broadly expressed across gastrointestinal and epithelial tumors, which explains why the company is simultaneously running a bevacizumab combination arm, planning a triplet chemotherapy combination study for the second half of 2026, and targeting non-CRC expansion cohorts in parallel. That is an aggressive multi-arm build for a company that raised $250 million in March and holds $346.7 million in cash. The PROBODY masking technology is the mechanism rationale here: EpCAM is expressed on normal epithelium too, and unmasked targeting would be dose-limiting. Conditional activation in the tumor microenvironment is what makes the therapeutic window plausible, not just the payload potency.
The CX-801 interferon alpha-2b program in melanoma is a quieter story but structurally interesting. Dose escalation in monotherapy has already exceeded the approved dose of unmasked interferon alpha-2b without prohibitive toxicity — that is the PROBODY platform proving its localization hypothesis in a systemic cytokine context. The combination arm with pembrolizumab is now in its third dose level. Initial combination data are expected by year-end. This program does not carry the near-term catalysts Varseta-M does, but it represents a different proof-of-concept: that the platform can rehabilitate a class of agents whose toxicity, not efficacy, ended their broad clinical use.
The metric that determines whether the registrational timeline holds is the response durability signal in the dose optimization cohort. Objective response rate in late-line CRC is achievable with several agents; what FDA will want to see before agreeing to a pivotal design is evidence that responses are not immediately transient. That depth-and-duration profile, not the headline response rate, is what the 2H 2026 readout must deliver.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
